|
liposarcoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
|
30795553 |
2019 |
|
liposarcoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Moreover, we found that FRS2 and FGFRs proteins are highly expressed and functional in three high-grade liposarcoma cell lines: FU-DDLS-1, LiSa-2, and SW872.
|
23393200 |
2013 |
|
liposarcoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Immunoblotting revealed high expression levels of phospho-FRS2 at Y436 and slightly overexpression of total FRS2 protein in liposarcoma but not in normal fat or preadipocytes.
|
21793095 |
2011 |
|
liposarcoma
|
0.330 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Microalbuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association meta-analyses and fine-mapping elucidate pathways influencing albuminuria.
|
31511532 |
2019 |
|
Neoplasms
|
0.070 |
GeneticVariation
|
group |
BEFREE |
Notably, we find recurrent ADGRG6 enhancer mutations and FRS2 duplications which are associated with higher protein expression in the tumor and poor prognosis.
|
30755618 |
2019 |
|
Neoplasms
|
0.070 |
PosttranslationalModification
|
group |
BEFREE |
Lenvatinib inhibited in vivo tumor growth in Hep3B2.1-7 and SNU-398 xenografts and decreased phosphorylation of FRS2 and Erk1/2 within the tumor tissues.
|
29733511 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These findings suggest that FRS2 is amplified consistently in ALT/WDL/DDLs and offer another avenue for the investigation of the biology of this tumour group.
|
29368794 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Moreover, restoration of FRS2 rescued the tumor suppressive role of miR-613 in Wilms' tumor cell growth and metastasis.
|
28829507 |
2017 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We found that FRS2-amplified cancer cell lines are dependent on FRS2 expression, and that FRS2 overexpression in immortalized human cell lines conferred the ability to grow in an anchorage-independent manner and as tumors in immunodeficient mice.
|
25368431 |
2015 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
MDM2 and FRS2 play important roles as a regulator of p53 and a mediator of FGF signaling, respectively, and thus are potential molecular targets for therapy in many different tumors.
|
24480864 |
2014 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
FRS2 and FRS3 expression was profiled in cell lines and clinical tumors of different grades.
|
22078327 |
2011 |
|
Liposarcoma, Dedifferentiated
|
0.040 |
Biomarker
|
disease |
BEFREE |
Recent studies identified consistent amplification of FRS2 gene in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma.
|
30001240 |
2018 |
|
Liposarcoma, Dedifferentiated
|
0.040 |
Biomarker
|
disease |
BEFREE |
This study indicates that FGFR inhibitors have therapeutic potential in the treatment of DDLPS with amplified FRS2.
|
27409346 |
2016 |
|
Liposarcoma, Dedifferentiated
|
0.040 |
Biomarker
|
disease |
BEFREE |
Attenuation of FRS2 protein in FU-DDLS-1 and LiSa-2 cell lines decreased the phosphorylated extracellular signal-regulated kinase 1/2 and AKT and repressed cell proliferation.
|
23393200 |
2013 |
|
Liposarcoma, Dedifferentiated
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Real time PCR showed FRS2 mRNA transcriptional upregulation in WDLS (n = 19) and DDLS (n = 13) but not in lipoma (n = 5) and normal fat (n = 9).
|
21793095 |
2011 |
|
Adult Liposarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
|
30795553 |
2019 |
|
Childhood Liposarcoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.
|
30795553 |
2019 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Knock-down on either MYCN or LMO1 has led to inhibition on proliferation, invasion, migration, and metastasis of NB cells, and knock-down of FRS2 resulted in increases in MYCN and LMO1 expression and enhanced invasion, migration and metastasis of NB cells.
|
30321496 |
2019 |
|
Atypical Lipoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recent studies identified consistent amplification of FRS2 gene in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma.
|
30001240 |
2018 |
|
Atypical Lipoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
FRS2 amplification was detected in 136 of 146 (93.2%) ALT/WDL/DDLs, including 63 ALT/WDLs and 73 DDLs.
|
29368794 |
2018 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
These findings pinpoint coincidence detection of bFGF and TGF-β signaling by FRS2 as a mechanism that controls tumor cell invasion.
|
29949765 |
2018 |
|
Liposarcoma, well differentiated
|
0.030 |
Biomarker
|
disease |
BEFREE |
Recent studies identified consistent amplification of FRS2 gene in atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma.
|
30001240 |
2018 |
|
Liposarcoma, well differentiated
|
0.030 |
Biomarker
|
disease |
BEFREE |
FRS2 amplification was detected in 136 of 146 (93.2%) ALT/WDL/DDLs, including 63 ALT/WDLs and 73 DDLs.
|
29368794 |
2018 |